Market-Moving News for May 21st
$BDRX
$MMAT
$SPT
Biotechnology: Pharmaceutical Preparations
Health Care
Semiconductors
Technology
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Company | Date | Price Target | Rating | Analyst |
|---|---|---|---|---|
| 2/27/2026 | $9.00 | Buy → Hold | Canaccord Genuity | |
| 6/3/2025 | $24.00 | Overweight → Neutral | Cantor Fitzgerald | |
| 11/19/2024 | $28.00 | Sector Perform | Scotiabank | |
| 8/22/2024 | $28.00 | Sector Weight → Underweight | KeyBanc Capital Markets | |
| 5/3/2024 | Outperform → Mkt Perform | William Blair | ||
| 5/3/2024 | $80.00 → $44.00 | Buy → Neutral | Goldman | |
| 5/3/2024 | Overweight → Sector Weight | KeyBanc Capital Markets | ||
| 5/3/2024 | $72.00 → $45.00 | Outperform → Neutral | Robert W. Baird |
4 - Sprout Social, Inc. (0001517375) (Issuer)
4 - Sprout Social, Inc. (0001517375) (Issuer)
3 - Biodexa Pharmaceuticals Plc (0001643918) (Issuer)
4 - Sprout Social, Inc. (0001517375) (Issuer)
4 - Sprout Social, Inc. (0001517375) (Issuer)
CHICAGO, April 06, 2026 (GLOBE NEWSWIRE) -- Sprout Social, Inc. ("Sprout Social", the "Company") (NASDAQ:SPT), an industry-leading provider of cloud-based social media management software, today announced that it will report its financial results for the first quarter ending March 31, 2026 after market close on Thursday, May 7, 2026. The financial results and business highlights will be discussed on a conference call and webcast scheduled at 4:00 p.m. Central Time (5:00 p.m. Eastern Time) on Thursday, May 7, 2026. Online registration for this event conference call can be found at https://events.q4inc.com/analyst/. The live webcast of the conference call can be accessed from Sprout Social'
April 2, 2026 Biodexa Announces Partnership with Syngene To Manufacture MTX240 GMP Clinical Trial Supplies Biodexa Pharmaceuticals PLC (NASDAQ:BDRX) ("Biodexa" or "Company"), a clinical stage biopharmaceutical company developing a clinical stage biopharmaceutical company developing innovative products focused on the treatment or prevention of gastrointestinal cancers, is pleased to announce that it has partnered with Syngene International Ltd (BSE: 539268, NSE: SYNGENE) ("Syngene") for the manufacture of both MTX240 active pharmaceutical ingredient and dosage form. Commenting, Dan Palmer, Vice President, Technology at Biodexa said "We are delighted to be partnering with Syngene for the s
March 27, 2026 Biodexa Pharmaceuticals PLC("Biodexa" or the "Company" or, together with its subsidiaries, the "Group") Preliminary Results for the Year Ended 31 December 2025 Biodexa Pharmaceuticals PLC (NASDAQ:BDRX), a clinical-stage biopharmaceutical company developing innovative products focused on the treatment or prevention of gastrointestinal cancers, announces its audited preliminary results for the year ended 31 December 2025. For more information, please contact: Biodexa Pharmaceuticals PLC Stephen Stamp, CEO Fiona Sharp, CFOTel: +44 (0)29 2048 0180www.biodexapharma.com About Biodexa The Company's lead development programs include eRapa, under development for Familial Adenoma
SCHEDULE 13G/A - Sprout Social, Inc. (0001517375) (Subject)
DEFA14A - Sprout Social, Inc. (0001517375) (Filer)
DEF 14A - Sprout Social, Inc. (0001517375) (Filer)
Canaccord Genuity downgraded Sprout Social from Buy to Hold and set a new price target of $9.00
Cantor Fitzgerald downgraded Sprout Social from Overweight to Neutral and set a new price target of $24.00
Scotiabank initiated coverage of Sprout Social with a rating of Sector Perform and set a new price target of $28.00
March 27, 2026 Biodexa Pharmaceuticals PLC("Biodexa" or the "Company" or, together with its subsidiaries, the "Group") Preliminary Results for the Year Ended 31 December 2025 Biodexa Pharmaceuticals PLC (NASDAQ:BDRX), a clinical-stage biopharmaceutical company developing innovative products focused on the treatment or prevention of gastrointestinal cancers, announces its audited preliminary results for the year ended 31 December 2025. For more information, please contact: Biodexa Pharmaceuticals PLC Stephen Stamp, CEO Fiona Sharp, CFOTel: +44 (0)29 2048 0180www.biodexapharma.com About Biodexa The Company's lead development programs include eRapa, under development for Familial Adenoma
January 05, 2026 Biodexa Pharmaceuticals PLC Appointment of Fiona Sharp to the Board as Chief Financial Officer and Company Secretary Biodexa Pharmaceuticals PLC ("Biodexa" or "the Company"), (NASDAQ:BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, is delighted to announce the promotion of Fiona Sharp to Chief Financial Officer and Company Secretary along with her election to the Board of Directors of the Company with immediate effect. Ms Sharp is a senior finance professional having joined the Company as Group Financial Controller in December 2019. During her tenure, she has consistentl
September 12, 2025 Biodexa Pharmaceuticals PLC("Biodexa" or the "Company") Interim results for the six months ended June 30, 2025 Biodexa Pharmaceuticals PLC (NASDAQ:BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, today announces its unaudited interim results for the six months ended June 30, 2025 which will also be made available on the Company's website at www.biodexapharma.com. OPERATIONAL HIGHLIGHTS The Company announced the following in the six months ended June 30, 2025: Allowance by the US Patent and Trademark Office of patent application No. 17/391-495 "Oral Rapamycin Nanopart
CHICAGO, April 06, 2026 (GLOBE NEWSWIRE) -- Sprout Social, Inc. ("Sprout Social", the "Company") (NASDAQ:SPT), an industry-leading provider of cloud-based social media management software, today announced that it will report its financial results for the first quarter ending March 31, 2026 after market close on Thursday, May 7, 2026. The financial results and business highlights will be discussed on a conference call and webcast scheduled at 4:00 p.m. Central Time (5:00 p.m. Eastern Time) on Thursday, May 7, 2026. Online registration for this event conference call can be found at https://events.q4inc.com/analyst/. The live webcast of the conference call can be accessed from Sprout Social'
Initiates Non-GAAP 30% Rule of 40 Target By the Fourth Quarter of 2027 Approximated Subscription Revenue Contribution for ≥$30K ARR Customers Grew 22% in 2025 CHICAGO, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Sprout Social, Inc. ("Sprout Social", the "Company") (NASDAQ:SPT), an industry-leading provider of cloud-based social media management software, today announced financial results for its fourth quarter ended December 31, 2025. "Our team delivered strong results in the fourth quarter, highlighted by 15% total RPO growth and strong non-GAAP profitability," said Ryan Barretto, CEO of Sprout Social. "We are announcing a new operating goal of reaching 30% on a non-GAAP basis against a Rule of 4
CHICAGO, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Sprout Social, Inc. ("Sprout Social", the "Company") (NASDAQ:SPT), an industry-leading provider of cloud-based social media management software, today announced that it will report its financial results for the fourth quarter ending December 31, 2025 after market close on Thursday, February 26, 2026. The financial results and business highlights will be discussed on a conference call and webcast scheduled at 4:00 p.m. Central Time (5:00 p.m. Eastern Time) on Thursday, February 26, 2026. Online registration for this event conference call can be found at https://events.q4inc.com/analyst/240954313?pwd=Fg5h0XTc. The live webcast of the conference cal
SC 13G/A - Biodexa Pharmaceuticals Plc (0001643918) (Subject)
SC 13G/A - Biodexa Pharmaceuticals Plc (0001643918) (Subject)
SC 13G - Sprout Social, Inc. (0001517375) (Subject)